Company: CERO
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001213900-25-044335
Chunk: 113

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-05-15
Form: 10-Q
Item: Item 2
Chunk 113
---
 2,252,376  
     (2,407,776) 
     (100.0)%

    Net loss 
     (5,105,931) 
     (2,299,694) 
     (2,806,237) 
     122.0%
  
    Deemed dividend on Series A, B and C Preferred Stock 
     (264,144) 
     -  
     (264,144) 
     100%
  
    Deemed dividend related to Series C Common Warrants 
     (84,083) 
     -  
     (84,083) 
     100%
  
    Net loss attributable to common stockholders 
    $(5,454,158) 
    $(2,299,694) 
    $(3,154,464) 
     137.2%

34

Research and Development Expenses

Research and development
expenses were $2.9 million for the three months ended March 31, 2025 as compared to $1.7 million for the three months ended March 31,
2024, reflecting an increase of $1.2 million. The increase was primarily attributable to an increase in clinal expenses of approximately
$1.3 million and an increase in scientific consulting fees of $0.4 million. During the three months ended March 31, 2025, we began clinical
trials related to the IND for CER-1236. This increase was primarily offset by a decrease in lab expenses of approximately $0.3 million
and a decrease in research and development salaries and benefits of approximately $0.1 million.

The Company anticipates that
its R&D expenses will significantly increase in the future as the Company increases headcount, compensation expense, and contracted
services for preclinical and clinical development of its product candidates, as well as for manufacturing of clinical product to be used
in clinical development.  

General and Administrative Expenses

General and administrative
expenses were $2.0 million for the three months ended March 31, 2025 as compared to $2.9 million for the three months ended March 31,
2024, reflecting a decrease of approximately $0.8 million. The decrease during the three months ended March 31, 2025 as compared to the
three months ended March 31, 2024, was primarily due to a decrease of $1.8 million in underwriting fees